Opportunities for Growth and Breakthroughs for Cell and Gene Therapies

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology, Trends in Manufacturing, May 2022, Volume 2022 eBook, Issue 2
Pages: 16-21

CGTs offer hope for the future of treatments, but the costly manufacturing, slow turnaround time, and need for supplies hinder progress.

A treatment that has been top-of-mind in recent years is cell and gene therapies (CGTs). Many companies and organizations investigate the potential of this type of treatment to address unmet medical needs. While significant headway has been made, CGTs are in their infancy. But with the potential to cure diseases, CGTs could change the future of treatments for certain conditions.

“[CGTs] offer for the first time the possibility to offer truly disease-modifying treatments, providing options for conditions considered intractable or where the current standard of care is insufficient,” says Bayer AG company sources.

Read this article in the Trends in Manufacturing ebook.



1. S. Fried et al., “Patients With Out of Specification Tisagenlecleucel Can Be Salvaged With Point-of-Care CART-T Cells: An Observational Intention-to-Treat Single-Center Analysis,” presentation at 2021 European Hematology Association Virtual Conference, EHA (Virtual, Aug. 15, 2021).

2. Stasiak, Andrzej. “Gene therapy,” EMBO Reports, March 5, 2001.

3. FDA, “FDA Approves Novel Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss,” FDA.gov, Press Release, Dec. 18, 2017.

About the author

Meg Rivers is a senior editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Article details

Pharmaceutical Technology
eBook: Trends in Manufacturing
May 2022
Pages: 16-21


When referring to this article, please cite it as M. Rivers, “Opportunities for Growth and Breakthroughs for Cell and Gene Therapies,” Pharmaceutical Technology Trends in Manufacturing eBook (May 2022).